Want to join the conversation?
Leerink Partners analyst Geoffrey Porges questions $GILD whether there is a stable outlook for HCV revenue on a market-by-market basis from its historic lows. COO Kevin Young says that there will be a gradual decline in new patient starts, but the company will, after copious amounts of testing and diagnoses with the CDC, hit an equilibrium.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.